Ifinatamab Deruxtecan (I-DXd) Clinical Trials
2 recruitingBiologic
Phase 12Phase 22
Showing 1–2 of 2 trials
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Small Cell Lung Cancer
Merck Sharp & Dohme LLC262 enrolled48 locationsNCT06780137
Recruiting
Phase 1Phase 2
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Merck Sharp & Dohme LLC450 enrolled46 locationsNCT04165070